Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
09:00am, Thursday, 21'st Aug 2025
Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech provides a corporate update and re
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
09:00am, Friday, 15'th Aug 2025
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of p
Active Energy, its pivot and the weird and wacky world of AIM
08:07am, Friday, 15'th Aug 2025
How do you make the leap from biomass to Bitcoin and battery storage? Active Energy Group PLC (AIM:AEG, OTCQB:ATGVF).
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
08:55am, Thursday, 14'th Aug 2025
OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Webull Financial Corporate Connec
Polarean Imaging makes key submission to US FDA
02:46am, Tuesday, 12'th Aug 2025
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has submitted a new phase III clinical trial protocol to the US Food and Drug Administration to support an expanded use of its lung imaging agent, XENOVIEW.
There will be presentations on the latest positive progress from AIM's clinical program in pancreatic cancer, the positive therapeutic effects of AIM's drug Ampligen on multiple cancer types, and Ampl
Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive si
Rockhopper Exploration is testing AIM's appetite for funding riskier opportunities
08:48am, Thursday, 31'st Jul 2025
Was it all a dream? Some kind of fevered hallucination?
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
11:12am, Monday, 28'th Jul 2025
Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. AIM is the late
Corero shares tumble 33% on profit warning and revenue shift
05:21am, Wednesday, 16'th Jul 2025
Shares in Corero Network Security PLC (AIM:CNS, OTCQB:DDoSF) dropped 33% on Wednesday morning after the cyber-defence firm warned that full-year revenue and earnings would fall short of market expecta
KEFI begins resettlement programme ahead of Tulu Kapi gold project launch
02:53am, Wednesday, 16'th Jul 2025
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has begun the community resettlement process for its Tulu Kapi gold project in Ethiopia, marking a key milestone in preparations to move into full-scale
Petro Matad brings in $4m in new investment
04:47am, Friday, 11'th Jul 2025
Petro Matad Limited (AIM:MATD, OTC:PRTDF), the AIM-quoted oil company operating in Mongolia, has raised $4 million through a placing and subscription of new shares, and has announced plans for a reta
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
08:55am, Wednesday, 02'nd Jul 2025
OCALA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a presentation and discussion on immunotherapies involving AIM
88 Energy extends exploration period in Namibia
03:37am, Wednesday, 02'nd Jul 2025
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) has announced a 12-month extension to its Namibia venture, where it plans to undertake a programme of early stage exploration. The AIM-quoted firm holds a 2
Savannah raises £4.8m to advance Portuguese lithium project with surge in retail and domestic support
02:33am, Wednesday, 02'nd Jul 2025
Savannah Resources PLC (AIM:SAV, ETR:SAV, OTC:SAVNF) has raised a total of £4.8 million in fresh investment after strong support from both institutional and individual investors, with the latest tra
